Correction: Adjuvant Targeted Treatment of Early Hormone Receptor-positive HER2-negative Breast Cancer: Olaparib, Abemaciclib or Ribociclib - Which One, How and For Whom? - Lukac S; Pfister K; Schäffler H; Leinert E; Fink A; Rack B; Fink V; Janni W; Heublein S (Geburtshilfe und Frauenheilkunde, 2025)